Table 2.

Sensitivity and specificity of RAPLOA with threshold of 40% (validation versus original data)

Source of Data	Indicator of high risk of severe Adverse reactions	Sensitivity	Specificity
Validation study in DRC	Prevalence of L. loa Mf > 20%	100.0	90.1
	Prevalence of L. loa 8,000+ Mf > 5%	96.3	87.5
	Prevalence of L. loa 30,000+ Mf > 2%	95.0	79.7
Original study in Cameroon and	Prevalence of L. loa Mf > 20%	100.0	92.4
Nigeria [8]	Prevalence of L. loa 8,000+ Mf > 5%	100.0	91.0
	Prevalence of L. loa 30,000+ Mf > 2%	100.0	79.2